Limits...
Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium.

Park YM, Kim CD, Lee JS - Korean J. Physiol. Pharmacol. (2015)

Bottom Line: Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels.Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL.As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Pusan National University School of Medicine & Medical Research Institute, Yangsan Pusan National University Hospital, Yangsan 626-770, Korea.

ABSTRACT
The purpose of this study was to compare the inhibitory effect of bevacizumab on human Tenon's fibroblasts (HTFs) cultured from primary and recurrent pterygium. Cultured HTFs were exposed to 2.0, 5.0, 7.5, and 15.0 mg/mL concentration of bevacizumab for 24 hours. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assays were then performed to assess fibroblast metabolism and viability. The matrix metalloproteinase (MMP), procollagen type I C terminal propeptide (PIP), and laminin immunoassays were performed to examine extracellular matrix production. Changes in cellular morphology were examined by phase-contrast and transmission electron microscopy. Both metabolic activity and viability of primary and recurrent pterygium HTFs were inhibited by bevacizumab in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels. Distinctly, the inhibitory effect of bevacizumab on MMP-1 level related with collagenase in primary pterygium HTFs was significantly higher than that of recurrent pterygium. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL. Only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Bevacizumab inhibits primary and recurrent pterygium HTFs in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

No MeSH data available.


Related in: MedlinePlus

Procollagen type 1 C terminal peptide (PIP) and laminin activity of primary and recurrent pterygium human Tenon's fibroblasts after exposure to bevacizumab.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4499648&req=5

Figure 4: Procollagen type 1 C terminal peptide (PIP) and laminin activity of primary and recurrent pterygium human Tenon's fibroblasts after exposure to bevacizumab.

Mentions: After exposure to bevacizumab, the levels of MMP-1, MMP-2, PIP, and laminin all decreased in a dose-dependent manner (Fig. 3 and 4). The MMP-1, PIP, and laminin production measured from primary and recurrent pterygium was significantly different from that of control HTFs at bevacizumab concentration of 7.5, 10.0, and 15.0 mg/mL (Fig. 3 and 4). Interestingly, MMP-1 level in primary pterygium HTFs were significantly higher than that of the recurrent pterygium HTFs (Fig. 3a).


Effect of Bevacizumab on Human Tenon's Fibroblasts Cultured from Primary and Recurrent Pterygium.

Park YM, Kim CD, Lee JS - Korean J. Physiol. Pharmacol. (2015)

Procollagen type 1 C terminal peptide (PIP) and laminin activity of primary and recurrent pterygium human Tenon's fibroblasts after exposure to bevacizumab.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4499648&req=5

Figure 4: Procollagen type 1 C terminal peptide (PIP) and laminin activity of primary and recurrent pterygium human Tenon's fibroblasts after exposure to bevacizumab.
Mentions: After exposure to bevacizumab, the levels of MMP-1, MMP-2, PIP, and laminin all decreased in a dose-dependent manner (Fig. 3 and 4). The MMP-1, PIP, and laminin production measured from primary and recurrent pterygium was significantly different from that of control HTFs at bevacizumab concentration of 7.5, 10.0, and 15.0 mg/mL (Fig. 3 and 4). Interestingly, MMP-1 level in primary pterygium HTFs were significantly higher than that of the recurrent pterygium HTFs (Fig. 3a).

Bottom Line: Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels.Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL.As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Pusan National University School of Medicine & Medical Research Institute, Yangsan Pusan National University Hospital, Yangsan 626-770, Korea.

ABSTRACT
The purpose of this study was to compare the inhibitory effect of bevacizumab on human Tenon's fibroblasts (HTFs) cultured from primary and recurrent pterygium. Cultured HTFs were exposed to 2.0, 5.0, 7.5, and 15.0 mg/mL concentration of bevacizumab for 24 hours. The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide and lactate dehydrogenase leakage assays were then performed to assess fibroblast metabolism and viability. The matrix metalloproteinase (MMP), procollagen type I C terminal propeptide (PIP), and laminin immunoassays were performed to examine extracellular matrix production. Changes in cellular morphology were examined by phase-contrast and transmission electron microscopy. Both metabolic activity and viability of primary and recurrent pterygium HTFs were inhibited by bevacizumab in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. Both types of HTFs had significant decreases in MMP-1, PIP, and laminin levels. Distinctly, the inhibitory effect of bevacizumab on MMP-1 level related with collagenase in primary pterygium HTFs was significantly higher than that of recurrent pterygium. Significant changes in cellular density and morphology both occurred at bevacizumab concentrations greater than 7.5 mg/mL. Only primary pterygium HTFs had a reduction in cellular density at a bevacizumab concentration of 5.0 mg/mL. Bevacizumab inhibits primary and recurrent pterygium HTFs in a dose-dependent manner, especially at concentrations greater than 7.5 mg/mL. As the primary HTFs produces larger amounts of MMP-1 compared to recurrent HTFs, significant reduction in MMP-1 level in primary pterygium HTFs after exposure to bevacizumab is likely to be related to the faster cellular density changes in primary pterygium HTFs.

No MeSH data available.


Related in: MedlinePlus